[Blocking of aldosterone receptors reduces the risk of events in patients with severe cardiac failure].
Opasich
C
C
Divisione di Cardiologia, Fondazione Salvatore Maugeri, IRCCS, Centro Medico di Pavia.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004070:Digitalis; D004232:Diuretics / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D012307:Risk Factors; D013148:Spironolactone / Q000627:therapeutic use*; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone